NeuroThera Labs Accelerates Autism Trial Enrollment with 26 Children in SCI-210 Study
Event summary
- NeuroThera Labs, a SciSparc subsidiary, has enrolled 26 children in its SCI-210 autism trial, targeting a total of 60 participants aged 5–18.
- The double-blind, placebo-controlled study evaluates the safety and efficacy of SCI-210, a combination of CBD and CannAmide™, compared to CBD monotherapy.
- The trial, conducted at Soroka Medical Center, uses ABC-C and CGI-I assessments to measure efficacy over a 20-week treatment period.
- NeuroThera aims to commercialize SCI-210 in Israel first, followed by expansion into additional markets upon regulatory approval.
The big picture
NeuroThera’s progress in the SCI-210 trial reflects growing interest in cannabinoid-based therapies for neurodevelopmental disorders. The dual-compound approach could differentiate it from existing CBD treatments if efficacy is proven. Success in this trial would strengthen SciSparc’s pipeline, which also includes programs for Tourette syndrome and Alzheimer’s disease.
What we're watching
- Trial Completion
- Whether NeuroThera can maintain enrollment momentum to reach the 60-child target and complete the trial within the planned timeline.
- Regulatory Pathway
- The pace at which NeuroThera advances SCI-210 through regulatory approvals, starting with Israel.
- Commercial Strategy
- How NeuroThera positions SCI-210 in the competitive landscape of autism spectrum disorder treatments.